Literature DB >> 20121687

Oseltamivir-resistant pandemic (H1N1) 2009 influenza in a severely ill patient: the first Australian case.

David J Speers1, Simon H Williams, Mary Pinder, Harry R Moody, Aeron C Hurt, David W Smith.   

Abstract

After a 10-day course of oral oseltamivir for pandemic (H1N1) 2009 influenza infection, a renal transplant recipient developed rapid-onset severe primary viral pneumonia due to oseltamivir-resistant virus. Respiratory failure progressed despite high-dose oral oseltamivir, nebulised zanamivir and cessation of immunosuppressive medications, but his condition improved with intravenous zanamivir. He subsequently died of non-respiratory complications. This is the first case of oseltamivir-resistant pandemic (H1N1) 2009 in Australia and the first report of resistance in a solid organ transplant recipient.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20121687     DOI: 10.5694/j.1326-5377.2010.tb03459.x

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  10 in total

1.  Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa.

Authors:  Timothy M Uyeki; Henry H Bernstein; John S Bradley; Janet A Englund; Thomas M File; Alicia M Fry; Stefan Gravenstein; Frederick G Hayden; Scott A Harper; Jon Mark Hirshon; Michael G Ison; B Lynn Johnston; Shandra L Knight; Allison McGeer; Laura E Riley; Cameron R Wolfe; Paul E Alexander; Andrew T Pavia
Journal:  Clin Infect Dis       Date:  2019-03-05       Impact factor: 9.079

Review 2.  Changing epidemiology of respiratory viral infections in hematopoietic cell transplant recipients and solid organ transplant recipients.

Authors:  Christian Renaud; Angela P Campbell
Journal:  Curr Opin Infect Dis       Date:  2011-08       Impact factor: 4.915

Review 3.  Systematic review of influenza resistance to the neuraminidase inhibitors.

Authors:  Kristian Thorlund; Tahany Awad; Guy Boivin; Lehana Thabane
Journal:  BMC Infect Dis       Date:  2011-05-19       Impact factor: 3.090

Review 4.  Two years after pandemic influenza A/2009/H1N1: what have we learned?

Authors:  Vincent C C Cheng; Kelvin K W To; Herman Tse; Ivan F N Hung; Kwok-Yung Yuen
Journal:  Clin Microbiol Rev       Date:  2012-04       Impact factor: 26.132

Review 5.  Influenza prevention and treatment in transplant recipients and immunocompromised hosts.

Authors:  Michael G Ison
Journal:  Influenza Other Respir Viruses       Date:  2013-11       Impact factor: 4.380

6.  Oseltamivir resistance in adult oncology and hematology patients infected with pandemic (H1N1) 2009 virus, Australia.

Authors:  Adrian R Tramontana; Biju George; Aeron C Hurt; Joseph S Doyle; Katherine Langan; Alistair B Reid; Janet M Harper; Karin Thursky; Leon J Worth; Dominic E Dwyer; C Orla Morrissey; Paul D R Johnson; Kirsty L Buising; Simon James Harrison; John F Seymour; Patricia E Ferguson; Bin Wang; Justin T Denholm; Allen C Cheng; Monica Slavin
Journal:  Emerg Infect Dis       Date:  2010-07       Impact factor: 6.883

7.  Inhibitory and combinatorial effect of diphyllin, a v-ATPase blocker, on influenza viruses.

Authors:  Hui-Wen Chen; Jenna Xiao Cheng; Ming-Tsan Liu; Kevin King; Ju-Yi Peng; Xin-Quan Zhang; Ching-Ho Wang; Sujan Shresta; Robert T Schooley; Yu-Tsueng Liu
Journal:  Antiviral Res       Date:  2013-06-29       Impact factor: 5.970

8.  Rapid detection of the H275Y oseltamivir resistance mutation in influenza A/H1N1 2009 by single base pair RT-PCR and high-resolution melting.

Authors:  Steven Y C Tong; Farshid Dakh; Aeron C Hurt; Yi-Mo Deng; Kevin Freeman; Peter K Fagan; Ian G Barr; Philip M Giffard
Journal:  PLoS One       Date:  2011-06-24       Impact factor: 3.240

Review 9.  A Review of the Antiviral Susceptibility of Human and Avian Influenza Viruses over the Last Decade.

Authors:  Ding Yuan Oh; Aeron C Hurt
Journal:  Scientifica (Cairo)       Date:  2014-04-02

10.  Influenza A/H3N2 virus infection in immunocompromised ferrets and emergence of antiviral resistance.

Authors:  Rueshandra Roosenhoff; Erhard van der Vries; Anne van der Linden; Geert van Amerongen; Koert J Stittelaar; Saskia L Smits; Martin Schutten; Ron A M Fouchier
Journal:  PLoS One       Date:  2018-07-19       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.